The US regulatory authority conducted the audit of Beximco Pharma's oral solid dosage facility at Tongi, during January 19-22, 2015, without issuing any 483 form. A 483 form is issued when FDA has observations of non-compliance or deviation from Good Manufacturing Practices (GMP).
This is for the first time US FDA has conducted audit in a pharma f...
Beximco Pharma completes US FDA Audit
Beximco Pharma becomes the first Bangladeshi company to be audited by the US Food and Drug Administration (US FDA), which is globally known for its stringent regulatory standards.
The US regulatory authority conducted the audit of Beximco Pharma's oral solid dosage facility at Tongi, during January 19-22, 2015, without issuing any 483 form. A 483 form is issued when FDA has observations of non-compliance or deviation from Good Manufacturing Practices (GMP).
This is for the first time US FDA has conducted audit in a pharma f...
The US regulatory authority conducted the audit of Beximco Pharma's oral solid dosage facility at Tongi, during January 19-22, 2015, without issuing any 483 form. A 483 form is issued when FDA has observations of non-compliance or deviation from Good Manufacturing Practices (GMP).
This is for the first time US FDA has conducted audit in a pharma f...























